PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
 
PLoS One. 2010; 5(10): e13136.
Published online 2010 October 1. doi:  10.1371/journal.pone.0013136
PMCID: PMC2948524

Neutralisation of Interleukin-13 in Mice Prevents Airway Pathology Caused by Chronic Exposure to House Dust Mite

Benjamin Edward Rich, Editor

Abstract

Background

Repeated exposure to inhaled allergen can cause airway inflammation, remodeling and dysfunction that manifests as the symptoms of allergic asthma. We have investigated the role of the cytokine interleukin-13 (IL-13) in the generation and persistence of airway cellular inflammation, bronchial remodeling and deterioration in airway function in a model of allergic asthma caused by chronic exposure to the aeroallergen House Dust Mite (HDM).

Methodology/Principal Findings

Mice were exposed to HDM via the intranasal route for 4 consecutive days per week for up to 8 consecutive weeks. Mice were treated either prophylactically or therapeutically with a potent neutralising anti-IL-13 monoclonal antibody (mAb) administered subcutaneously (s.c.). Airway cellular inflammation was assessed by flow cytometry, peribronchial collagen deposition by histocytochemistry and airway hyperreactivity (AHR) by invasive measurement of lung resistance (RL) and dynamic compliance (Cdyn). Both prophylactic and therapeutic treatment with an anti-IL-13 mAb significantly inhibited (P<0.05) the generation and maintenance of chronic HDM-induced airway cellular inflammation, peribronchial collagen deposition, epithelial goblet cell upregulation. AHR to inhaled methacholine was reversed by prophylactic but not therapeutic treatment with anti-IL-13 mAb. Both prophylactic and therapeutic treatment with anti-IL-13 mAb significantly reversed (P<0.05) the increase in baseline RL and the decrease in baseline Cdyn caused by chronic exposure to inhaled HDM.

Conclusions/Significance

These data demonstrate that in a model of allergic lung disease driven by chronic exposure to a clinically relevant aeroallergen, IL-13 plays a significant role in the generation and persistence of airway inflammation, remodeling and dysfunction.

Introduction

Chronic exposure of the human airway to inhaled allergen drives inflammatory processes and remodels airway structure, resulting in the development of clinical symptoms of asthma. A mouse disease model driven by chronic exposure of the airway to whole house dust mite extract (HDM) has been developed to more accurately understand the dynamic pathophysiological mechanisms linking allergen-induced airway inflammation, structural changes and dysfunction. HDM is a clinically relevant aeroallergen known to activate the immune system through pattern recognition receptors [1][3] and proteolytic activity [4]. The HDM model shares many pathological features with persistent human asthma, notably eosinophilic airway inflammation, mucus hypersecretion, fibrosis of the airway wall and airway hyperreactivity (AHR) to methacholine [5]. The objective of the work detailed herein was to determine the role of interleukin-13 (IL-13) in the generation and persistence of airway pathology caused by chronic exposure to HDM.

IL-13 is a Th2 cytokine structurally and functionally related to IL-4 [6]. In contrast to IL-4, IL-13 is unable to polarise T cells or induce their proliferation [7]. The central role of IL-13 is considered to be perpetuation of inflammation through the upregulation of adhesion molecules, metalloproteinases, chemokines and cytokines [8]. In asthmatic patients IL-13 mRNA and protein is elevated in bronchoalveolar lavage fluid (BAL) following airway allergen challenge [9][13]. Bronchial expression of IL-13 mRNA positively correlates with the number of eosinophils in BAL [12] and bronchial biopsy [11]. Furthermore, IL-13 protein is elevated in sputum from asthmatic patients, and the number of sub-mucosal cells expressing IL-13 is increased [14], [15]. Sub-mucosal cells expressing IL-13 have been identified as eosinophils [14] and mast cells [16] although many other cell types are capable of producing IL-13 in the inflamed airway. Notably, T-lymphocytes (predominantly, but not exclusively Th2 cells) represent a major source of IL-13, in addition to macrophages, basophils, dendritic cells, airway smooth muscle [7], [8], and invariant NKT cells [17].

Administration of recombinant IL-13 directly to the mouse airway, or transgenic over-expression of IL-13 in the airway, is sufficient to induce a phenotype resembling human asthma pathology, characterised by eosinophilia, airway remodelling, goblet cell upregulation, mucus hypersecretion and AHR [18][21]. The pharmacology of neutralising anti-IL-13 monoclonal antibodies (mAb) has been investigated in experimental models of asthma in mice [18], [22], sheep [23] and non-human primates [24], [25]. Direct evidence for a role of IL-13 in human asthma has been reported by Gauvreau et. al. (European Respiratory Society, Berlin 2008, oral communication) who demonstrated that the anti-IL-13 mAb IMA-638 significantly inhibited allergen-induced early and late phase bronchoconstriction in patients with mild allergic asthma.

The aim of this study was to determine whether IL-13 has a causative role in the pathogenesis of airway inflammation, remodelling and dysfunction stimulated by chronic exposure of mice to inhaled HDM in the absence of adjuvant or peripheral sensitisation. Furthermore, we sought to determine the importance of IL-13 during both the development and maintenance of established airway pathology caused by chronic exposure to HDM. The aim of the study was met. Using an anti-IL-13 neutralising mAb we demonstrated that IL-13 is important for both the development and maintenance of airway pathology caused by pulmonary sensitisation to HDM.

Results

Neutralisation of IL-13 inhibits airway cellular inflammation

IL-13 protein was upregulated in the lungs after 5 weeks of exposure to HDM, following the protocol in Figure 1A (4.19±0.38 pg/mg in mice exposed to saline; 7.62±0.79 pg/mg in mice exposed to HDM, p<0.01, Figure 2A). Similarly IL-13 mRNA was significantly elevated in mice exposed to HDM when compared to mice exposed to saline (670±113 fold, p<0.001, Figure 2B). Five consecutive weeks of exposure to HDM via the intra-nasal route stimulated cellular inflammation of the airways, observed as an elevation in BAL eosinophils, neutrophils and T-lymphocytes (Figure 3). To determine the role of IL-13 in the cellular inflammatory response, mice were treated prophylactically with anti-IL-13 mAb s.c. immediately prior to the first exposure to intranasal HDM and weekly s.c. thereafter. Prophylactic treatment with anti-IL-13 mAb (10 mg/kg) significantly inhibited total CD45+ leukocyte numbers in BAL fluid by 44% (Figure 3A) and significantly inhibited the number of siglec-F+ eosinophils in BAL by 85% (Figure 3B). Anti-IL-13 treatment significantly reduced total CD4+ T-lymphocyte numbers in BAL by 46% (Figure 3C) and T1ST2+ Th2 lymphocytes by 60% (Figure 3D). Neutrophil numbers in BAL were unaffected by treatment with anti-IL-13 mAb (Figure 3E).

Figure 1
Experimental protocols for chronic exposure to house dust mite (HDM).
Figure 2
Up regulation of IL-13 in HDM sensitised mice.
Figure 3
Effect of IL-13 neutralisation on BAL leukocytes.

To determine the role of IL-13 in maintaining the cellular inflammatory response in established disease, mice were exposed to HDM for 5 consecutive weeks prior to therapeutic administration of anti-IL-13 mAb (10 mg/kg, s.c., weekly), following the protocol in Figure 1B. Mice were subsequently exposed to HDM for a further 3 weeks, after which the BAL cellular infiltrate was characterised. Treatment with anti-IL-13 mAb using this therapeutic dosing regimen significantly reduced BAL CD45+ leukocytes by 44% (Figure 3F), siglec-F+ eosinophils by 59%; (Figure 3G), CD4+ T-lymphocytes by 57% (Figure 3H) and T1ST2+ Th2 lymphocytes by 43% (Figure 3I). No effects were observed on BAL neutrophil numbers (Figure 3J).

Neutralisation of IL-13 inhibits mucus cell upregulation

Airway mucus hypersecretion associated with goblet cell hyperplasia and metaplasia is a common feature of asthma that can be assessed in murine airway disease models by histological analysis of the airway epithelium. Intranasal administration of HDM for 5 consecutive weeks provoked a robust increase in the frequency of goblet cells within the airway epithelia, identified by AB/PAS staining (Figure 4B). Prophylactic treatment with anti-IL-13 mAb during the period of exposure to HDM significantly reduced goblet cell coverage (Figure 4D).

Figure 4
Effect of IL-13 neutralisation on epithelial goblet cell upregulation.

To investigate the role of IL-13 in maintaining elevated goblet cell number in established disease, mice were exposed to HDM for 5 consecutive weeks prior to commencement of treatment with anti-IL-13 mAb (10 mg/kg, s.c., weekly) and exposure to HDM for a further 3 weeks. As shown in Figure 4E, therapeutic treatment with anti-IL-13 mAb in established disease significantly reduced epithelial goblet cell coverage when compared to animals treated with vehicle.

Neutralisation of IL-13 inhibits airway wall remodelling

Administration of HDM to the airways of mice for 5 consecutive weeks significantly increased the thickness of sub-epithelial collagen as visualised with Masson's trichrome stain (Figure 5B). These data support the observations of Johnson et. al. made in a similar mouse model using HDM [5]. Prophylactic treatment with anti-IL-13 mAb significantly inhibited the increase in airway sub-epithelial collagen thickness stimulated by repeated exposure to HDM (Figure 5D).

Figure 5
Effect of IL-13 neutralisation on peribronchial collagen thickness.

Peribronchial sub-epithelial collagen thickness was further significantly increased when exposure to HDM was extended from 5 to 8 consecutive weeks (Figure 5E). Therapeutic treatment with anti-IL-13 mAb (10 mg/kg, s.c., weekly) starting from week 6 significantly prevented the additional increase in peribronchial collagen thickness stimulated by continued exposure to HDM.

Neutralisation of IL-13 inhibits AHR to methacholine and improves baseline RL and Cdyn

We have determined the effect of IL-13 neutralisation on lung function in the HDM model by assessment of RL and Cdyn at baseline and after methacholine exposure. Five consecutive weeks of intranasal HDM exposure caused a robust decline in lung function as shown by elevated baseline RL and reduced baseline Cdyn. Furthermore, HDM exposure resulted in hyperresponsiveness to inhaled methacholine demonstrated by percent change in RL and Cdyn relative to PBS response (Figure 6). Prophylactic treatment with anti-IL-13 mAb (10 mg/kg, s.c. weekly) normalised baseline RL and Cdyn to levels measured in animals exposed to saline (Figure 6A and 6B). Prophylactic treatment with anti-IL-13 mAb significantly and robustly inhibited AHR to inhaled methacholine (Figure 6C and 6D).

Figure 6
Effect of IL-13 neutralisation on lung function and AHR to inhaled MCh.

The therapeutic dosing protocol was employed to determine the role of IL-13 in maintaining changes in lung function in established disease (Figure 1B). Therapeutic treatment with anti-IL-13 mAb from week 6 of exposure to HDM significantly improved baseline RL and Cdyn measured at week 8 (Figure 6E and 6F, respectively). However, therapeutic treatment with anti-IL-13 mAb from week 6 did not inhibit AHR to inhaled methacholine measured at week 8 (Figure 6G and 6H). In contrast to the robust effect of prophylactic anti-IL-13 mAb treatment on AHR to methacholine, therapeutic treatment did not inhibit AHR despite reversing changes in baseline lung function.

Discussion

In this study we have demonstrated that neutralisation of IL-13 in mice prevents the development and persistence of pathological and functional changes in the airways caused by repeated exposure to HDM.

We have employed an experimental protocol using repeated, prolonged inhaled administration of HDM, in the absence of experimental adjuvants or peripheral sensitisation, to more faithfully model the exposure to allergen experienced by asthmatic patients. Previous studies have shown that chronic exposure of mice to HDM results in immunological changes and airway pathology similar to that observed in persistent asthma. Johnson et.al. report that chronic exposure of mice to inhaled HDM for 5 days per week for up to 7 consecutive weeks stimulated a robust helper T cell Type 2 (Th2) response, accumulation of inflammatory leukocytes in the lung parenchyma and airways, peribronchial collagen deposition, epithelial goblet cell upregulation and AHR to the non-specific inhaled spasmogen methacholine [5]. In the present study we demonstrate that repeated and continuous administration of HDM caused accumulation of proinflammatory effector leukocytes in the airway. Furthermore, in agreement with the observations of Johnson et. al. [5], we found that chronic exposure to HDM caused increased collagen deposition in the bronchial wall, epithelial goblet cell hyperplasia and AHR to methacholine. Chronic exposure of mice to HDM, without experimental adjuvant, resulted in significantly increased baseline lung RL, and decreased Cdyn, measured 24 h after the last HDM challenge. This is a useful surrogate for the late asthmatic response and demonstrates how chronic exposure to HDM results in fundamental changes in airway dynamics.

Prophylactic and therapeutic treatment with a high affinity, potent, neutralising anti-IL-13 mAb significantly inhibited HDM-induced airway eosinophilia, goblet cell upregulation and peribronchial collagen deposition. In addition anti-IL-13 treatment significantly inhibited Th2 cell accumulation in the airway. These data are in agreement with previous reports identifying a central role for IL-13 in the generation and maintenance of the murine allergic airways response following adjuvant-enhanced systemic sensitisation and inhaled exposure to ovalbumin [22], [26], aspergillus [27] or house dust mite [28]. Our data presented herein are the first demonstrating the importance of IL-13 in maintaining airway pathology in a disease model established using a clinically relevant aeroallergen administered by the inhaled route only and without the use of experimental adjuvants or peripheral sensitisation.

In asthmatic patients AHR to inhaled spasmogens is an indicator of poor disease control, and is associated with other relevant outcome measures such as lung function and markers of lung inflammation [29]. It has been shown clinically in allergic asthmatic patients that neutralisation of IL-13 improves lung function following inhaled allergen challenge, but does not prevent AHR to methacholine (Gauvreau et. al., European Respiratory Society Berlin 2008, oral communication). A similar lack of effect on AHR in asthmatic patients was observed using pitrakinra, an IL-4 receptor antagonist that blocks IL-13 and IL-4 binding to IL-4Rα [30]. In contrast, neutralisation of IL-13 has been shown to reduce AHR to inhaled spasmogens in mouse [22] and sheep [23] models of asthma. We observe that prophylactic treatment with anti-IL-13 mAb reduced AHR to methacholine, prevented the increase in baseline airway resistance, RL, and decrease in dynamic compliance, Cdyn, measured 24 h after allergen challenge. The effect we observe on baseline RL and Cdyn is consistent with that obtained in an ovalbumin-driven model in mice using IL-13R-Fc to neutralise IL-13 [26]. Therapeutic treatment with anti-IL-13 mAb however reversed the HDM induced changes in baseline RL and Cdyn without effecting methacholine provoked AHR. In this study we observe differential effects of anti-IL-13 mAb on AHR to methacholine following prophylactic and therapeutic treatment. Our data support the existing evidence that anti-IL-13 mAb are effective in reducing AHR to inhaled spasmogens in preclinical models, but not AHR to inhaled spasmogens in asthma patients treated therapeutically. Furthermore our data support the evidence that IL-13 is important for the late phase decline in lung function in preclinical models and in asthma patients. There are therapeutics in clinical use, for example the anti-IgE mAb omalizumab, that do not affect AHR to methacholine in asthma patients, but do improve the late phase decline in lung function and reduce the number of disease exacerbations [31], [32]. We are currently conducting studies in a mouse model of asthma exacerbation to investigate the efficacy of anti-IL-13 mAb therapy on the decline in lung function and AHR caused by exposure to HDM with concomitant viral infection.

IL-13 may act directly on airway smooth muscle, causing airway hyperreactivity to inhaled spasmogens and increase baseline RL. Studies have shown that IL-13 can directly act on airway smooth muscle cells to increase contractility [33] and upregulate leukotriene receptors [34]. IL-13 has been shown to stimulate autocrine release of IL-5 from ASM, resulting in hyperresponsiveness sensitive to inhibition with an anti-IL-5 mAb [35]. In addition of effects on ASM contractility, the effect of IL-13 on baseline RL and Cdyn may be attributable structural changes such as bronchial fibrosis, goblet cell hyperplasia, and associated mucus hypersecretion causing airway obstruction. Indeed, mucus plugs were observed in the airways of some mice following exposure to HDM (data not shown).

The chronic HDM model of asthma has enabled us to investigate the effect of anti-IL-13 mAb treatment on both mechanism and disease-relevant endpoints. The effect of anti-IL-13 treatment on mechanism-based endpoints, for example inhibition of airway eosinophilia, are important for understanding the pharmacology of anti-IL-13 mAb and are findings consistent with IL-13 stimulating local production of the eosinophil chemoattractant eotaxin [36]. We suggest that the robust efficacy of anti-IL-13 mAb on disease-relevant endpoints in this model indicates where the benefit of anti-IL-13 therapeutics may be seen in clinical practice. Thus, inhibition of chronic mucus hypersecretion, prevention of continued peribronchial collagen deposition and decreased airway wall compliance would represent effects of IL-13 neutralisation with the potential to fundamentally affect disease progression [37], [38].

In conclusion, these data demonstrate that IL-13 neutralisation reduces airway inflammation, normalises baseline lung function and reduces AHR to inhaled spasmogen in a mouse model of asthma driven by a clinically relevant aeroallergen administered by the inhaled route only, and without the use of experimental adjuvants. Our data support the proposition that neutralisation of IL-13 will benefit patients with chronic persistent asthma by reducing airway inflammation and improving lung function, with the potential to reduce the number and severity of exacerbations and the need for corticosteroids.

Materials and Methods

Antibody generation

Murinised anti-mouse IL-13 mAb (CA154_582, mAb A) was generated by UCB and in vitro activity was characterised as reported previously [39]. CA154_582 prevents the interaction between IL-13 and IL-13Rα1 and hence the subsequent association with IL-4Rα (KD 11pM). In addition this anti-IL-13 mAb blocks IL-13 binding IL-13Rα2.

Mice

Male Balb/c mice (20–25 g) were obtained from Harlan (UK). All mice were housed in specific pathogen free conditions, in standard cages and provided with food and water ad libitum. All experiments were performed in accordance with the UK Animals (Scientific Procedures) Act 1986.

HDM sensitisation and treatment

Male Balb/c mice were exposed to 25 µg HDM protein (Greer, USA) in 25 µl sterile saline via the intra-nasal (i.n.) route under light Isoflurane anaesthesia for 4 consecutive days per week for 5 or 8 weeks. Control mice received 25 µl sterile saline administered i.n. under light Isoflurane anaesthesia for 4 consecutive days per week for 5 or 8 weeks. Mice were treated with 10 mg/kg anti-IL-13 mAb s.c. immediately prior to HDM administration on day 0 or 35 as indicated, and weekly thereafter. HDM sensitised control mice were dosed with control mouse IgG (10 mg/kg mAb 101.4) accordingly. Mice were killed 24 hours after the final HDM exposure. Where therapeutic dosing was employed an additional HDM sensitised group was killed on day 35 for lung histological analysis immediately prior to anti-IL-13 treatment (Figure 1).

Measurement of lung IL-13 mRNA and protein

Lung tissue IL-13 mRNA levels were determined in medial lung lobes relative to 18S expression as previously described in detail [39]. IL-13 mRNA expression was normalised to that of lungs from animals exposed to saline. For determination of IL-13 protein in lung tissue, cranial lung lobes were homogenized at 50 mg tissue/ml in HBSS containing ‘complete’ protease inhibitor cocktail (Roche, UK), prior to centrifugation (20800× g, 20 min) and measurement of IL-13 in supernatant by ELISA (R&D Systems, UK).

Flow cytometry

BAL sampling was performed post mortem via tracheal cannula with 3×0.4 ml PBS (containing 0.4% v/w BSA, 12 mM HEPES and 500 mM EDTA). BAL cell suspensions were stained with combinations of anti-mouse CD4, siglec F, Gr-1, CD45 (BD Biosciences, UK) and T1ST2 (MDbiosciences, USA). BAL samples were incubated with the antibody cocktail for 20 minutes on ice. BAL samples were fixed and red cells lysed with BD FACSlyse (BD Biosciences, UK) prior to centrifugation (400× g, 10 min, RT) and resuspension in PKH26 microbeads (Sigma, UK) for quantification of events acquired. Total leukocytes were identified as CD45+, CD4+ T-lymphocytes as CD45+ CD4+, Th2 cells as CD45+ CD4+ T1ST2+, eosinophils as CD45+ siglec F+ and neutrophils as CD45+ Gr-1hi. Flow cytometric acquisition was performed using the FACSCanto II system (BD Biosciences, UK) with offline analysis using Flowjo (version 8.8.4, Tree Star, USA).

Histology

The left lung was excised post mortem and preserved in 10% formalin (Surgipath, UK), embedded in paraffin and sectioned for staining with Alcian blue periodic acid Schiff's stain (AB/PAS) for mucin or Masson's Trichrome for collagen. Goblet cell upregulation within the airway epithelia was assessed by measuring the length of airway basement membrane covered by goblet cells, expressed as a percentage of total basement membrane length in each airway. Three bronchioles were selected at random from each section; one section was analysed per mouse and the mean goblet cell coverage (%) was calculated for each mouse. Peribronchial collagen thickness was measured using Image-Pro Plus software (version 5, Media Cybernetics, USA). Three bronchioles were selected at random from each section and the mean depth of collagen from the basement membrane determined from five measurements around the bronchiole. One section was analysed per mouse and the mean collagen depth was calculated for each mouse.

Measurement of Airway Hyperreactivity

AHR was determined by direct measurement of lung resistance (RL) and dynamic compliance (Cdyn) in anaesthetised, ventilated mice using FinePointe apparatus (Buxco, USA). Twenty four hours after HDM instillation mice were terminally anaesthetised with ketamine (200 mg/kg, i.m.) and pentobarbital (35 mg/kg, i.p.), tracheotomised and ventilated at 160 breaths/min, tidal volume 200 µl. After a short period of acclimatisation baseline measurements of lung function were recorded. Mice were then exposed to aerosolised PBS and subsequently increasing concentrations of aerosolised methacholine via the tracheal cannula (3–100 mg/ml, Sigma, UK). AHR data is expressed as percent change from PBS response.

Statistical analysis

Data are representative of two or more studies. Data are expressed as mean ± SEM, unless otherwise stated. Statistical significance was determined by parametric one-way analysis of variance (ANOVA) with Dunnett's post test. Differences from vehicle control are denoted by asterisks whereby * P<0.05, ** P<0.01 and ***P<0.001. Graph generation and statistical analyses were performed using GraphPad Prism (version 5.01).

Footnotes

Competing Interests: This study was funded entirely by UCB. All authors were employees of UCB at the time these studies were performed. This does not alter the adherence of all authors to all policies of PLoS ONE involving the sharing of data and materials.

Funding: This study was funded entirely by UCB (www.ucb.com). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. All authors were employees of UCB at the time these studies were performed.

References

1. Willart MA, Lambrecht BN. The danger within: endogenous danger signals, atopy and asthma. Clin Exp Allergy. 2009;39:12–19. [PubMed]
2. Chiou YL, Lin CY. Der p2 activates airway smooth muscle cells in a TLR2/MyD88-dependent manner to induce an inflammatory response. J Cell Physiol. 2009;220:311–318. [PubMed]
3. Trompette A, Divanovic S, Visintin A, Blanchard C, Hegde RS, et al. Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein. Nature. 2009;457:585–588. [PMC free article] [PubMed]
4. Hewitt CR, Foster S, Phillips C, Horton H, Jones RM, et al. Mite allergens: significance of enzymatic activity. Allergy. 1998;53:60–63. [PubMed]
5. Johnson JR, Wiley RE, Fattouh R, Swirski FK, Gajewska BU, et al. Continuous Exposure to House Dust Mite Elicits Chronic Airway Inflammation and Structural Remodeling. Am J Respir Crit Care Med. 2004;169:378–385. [PubMed]
6. Wynn TA. IL-13 effector functions. Annu Rev Immunol. 2003;21:425–456. [PubMed]
7. de Vries JE. The role of IL-13 and its receptor in allergy and inflammatory responses. J Allergy Clin Immunol. 1998;102:165–169. [PubMed]
8. Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol Rev. 2004;202:175–190. [PubMed]
9. Huang SK, Xiao HQ, Kleine-Tebbe J, Paciotti G, Marsh DG, et al. IL-13 expression at the sites of allergen challenge in patients with asthma. J Immunol. 1995;155:2688–2694. [PubMed]
10. Kroegel C, Julius P, Matthys H, Virchow JC, Jr, Luttmann W. Endobronchial secretion of interleukin-13 following local allergen challenge in atopic asthma: relationship to interleukin-4 and eosinophil counts. Eur Respir J. 1996;9:899–904. [PubMed]
11. Humbert M, Durham SR, Kimmitt P, Powell N, Assoufi B, et al. Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J Allergy Clin Immunol. 1997;99:657–665. [PubMed]
12. Prieto J, Lensmar C, Roquet A, Van DP, I, Gigliotti D, et al. Increased interleukin-13 mRNA expression in bronchoalveolar lavage cells of atopic patients with mild asthma after repeated low-dose allergen provocations. Respir Med. 2000;94:806–814. [PubMed]
13. Batra V, Musani AI, Hastie AT, Khurana S, Carpenter KA, et al. Bronchoalveolar lavage fluid concentrations of transforming growth factor (TGF)-beta1, TGF-beta2, interleukin (IL)-4 and IL-13 after segmental allergen challenge and their effects on alpha-smooth muscle actin and collagen III synthesis by primary human lung fibroblasts. Clin Exp Allergy. 2004;34:437–444. [PubMed]
14. Berry MA, Parker D, Neale N, Woodman L, Morgan A, et al. Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis. J Allergy Clin Immunol. 2004;114:1106–1109. [PubMed]
15. Saha SK, Berry MA, Parker D, Siddiqui S, Morgan A, et al. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. Journal of Allergy and Clinical Immunology. 2008;121:685–691. [PubMed]
16. Brightling CE, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID, et al. Interleukin-4 and -13 expression is co-localized to mast cells within the airway smooth muscle in asthma. Clin Exp Allergy. 2003;33:1711–1716. [PubMed]
17. Kim EY, Battaile JT, Patel AC, You Y, Agapov E, et al. Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nat Med. 2008;14:633–640. [PMC free article] [PubMed]
18. Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science. 1998;282:2261–2263. [PubMed]
19. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, et al. Interleukin-13: central mediator of allergic asthma. Science. 1998;282:2258–2261. [PubMed]
20. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest. 1999;103:779–788. [PMC free article] [PubMed]
21. Kuperman DA, Huang X, Koth LL, Chang GH, Dolganov GM, et al. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med. 2002;8:885–889. [PubMed]
22. Yang G, Volk A, Petley T, Emmell E, Giles-Komar J, et al. Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling. Cytokine. 2004;28:224–232. [PubMed]
23. Kasaian MT, Donaldson DD, Tchistiakova L, Marquette K, Tan XY, et al. Efficacy of IL-13 neutralization in a sheep model of experimental asthma. Am J Respir Cell Mol Biol. 2007;36:368–376. [PubMed]
24. Bree A, Schlerman FJ, Wadanoli M, Tchistiakova L, Marquette K, et al. IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J Allergy Clin Immunol. 2007;119:1251–1257. [PubMed]
25. Kasaian MT, Tan XY, Jin M, Fitz L, Marquette K, et al. Interleukin-13 neutralization by two distinct receptor blocking mechanisms reduces immunoglobulin E responses and lung inflammation in cynomolgus monkeys. J Pharmacol Exp Ther. 2008;325:882–892. [PubMed]
26. Taube C, Duez C, Cui ZH, Takeda K, Rha YH, et al. The role of IL-13 in established allergic airway disease. J Immunol. 2002;169:6482–6489. [PubMed]
27. Blease K, Jakubzick C, Westwick J, Lukacs N, Kunkel SL, et al. Therapeutic effect of IL-13 immunoneutralization during chronic experimental fungal asthma. J Immunol. 2001;166:5219–5224. [PubMed]
28. Goplen N, Karim MZ, Liang Q, Gorska MM, Rozario S, et al. Combined sensitization of mice to extracts of dust mite, ragweed, and Aspergillus species breaks through tolerance and establishes chronic features of asthma. J Allergy Clin Immunol. 2009;123:925–932. [PMC free article] [PubMed]
29. Langley SJ, Goldthorpe S, Custovic A, Woodcock A. Relationship among pulmonary function, bronchial reactivity, and exhaled nitric oxide in a large group of asthmatic patients. Ann Allergy Asthma Immunol. 2003;91:398–404. [PubMed]
30. Wenzel S, Wilbraham D, Fuller R, Getz E, Lonphre M. Effect of an interieukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet. 2007;370:1422–1431. [PubMed]
31. van Rensen EL, Evertse CE, van Schadewijk WA, van Wijngaarden S, Ayre G, et al. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy. 2009;64:72–80. [PubMed]
32. Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004;34:632–638. [PubMed]
33. Tliba O, Deshpande D, Chen H, Van Besien C, Kannan M, et al. IL-13 enhances agonist-evoked calcium signals and contractile responses in airway smooth muscle. Br J Pharmacol. 2003;140:1159–1162. [PMC free article] [PubMed]
34. Espinosa K, Bosse Y, Stankova J, Rola-Pleszczynski M. CysLT1 receptor upregulation by TGF-beta and IL-13 is associated with bronchial smooth muscle cell proliferation in response to LTD4. J Allergy Clin Immunol. 2003;111:1032–1040. [PubMed]
35. Grunstein MM, Hakonarson H, Leiter J, Chen M, Whelan R, et al. IL-13-dependent autocrine signaling mediates altered responsiveness of IgE-sensitized airway smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2002;282:L520–L528. [PubMed]
36. Wenzel SE, Trudeau JB, Barnes S, Zhou X, Cundall M, et al. TGF-beta and IL-13 synergistically increase eotaxin-1 production in human airway fibroblasts. J Immunol. 2002;169:4613–4619. [PubMed]
37. Rogers DF. Physiology of airway mucus secretion and pathophysiology of hypersecretion. Respir Care. 2007;52:1134–1146. [PubMed]
38. Warner SM, Knight DA. Airway modeling and remodeling in the pathogenesis of asthma. Curr Opin Allergy Clin Immunol. 2008;8:44–48. [PubMed]
39. Berry LM, Adams R, Airey M, Bracher MG, Bourne T, et al. In vitro and in vivo characterisation of anti-murine IL-13 antibodies recognising distinct functional epitopes. International Immunopharmacology. 2009;9:201–206. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science